Over the last few days, we’ve covered data from the leading checkpoint inhibitors from BMS, Merck and Roche, but what about other agents in development in immuno-oncology? One of the companies that burst on the scene in Chicago at ASCO 2014 with solid data was AstraZeneca with their anti-PD-L1, MEDI4736.

To put progress in context, last year Merck had one single abstract for MK–3475 (pembrolizumab), whereas this year MEDI4736 debuted with 7 abstracts, including several Trials in Progress posters in combination with their anti-CTLA4, tremelimumab, plus some important oral presentations too.

The last morning of the final day of the ASCO conference has not exactly been well attended in past years, especially in Developmental Therapeutics. This year was different – the large hall was jam packed and it was standing room only. I was lucky to get one of the last seats in the front row a good 15–20 mins early!

As we were waiting for the proceedings to start, the Japanese doctor sitting next to me turned and said:

“What do you think of this compound? I’m not expecting much, and they are behind the others already!”

To learn more about my insights from ASCO 2014, you can sign up or sign in below:

 AstraZeneca MEDI4736 shows Immuno Oncology promise at ASCO 2014

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $399 for 3 months access (does not auto renew), and $1200 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals contained within it.